These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35836236)

  • 1. A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses.
    Chen S; Yang L; Ou X; Li JY; Zi CT; Wang H; Hu JM; Liu Y
    J Nanobiotechnology; 2022 Jul; 20(1):320. PubMed ID: 35836236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.
    Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y
    Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2.
    Ross KA; Kelly S; Phadke KS; Peroutka-Bigus N; Fasina O; Siddoway A; Mallapragada SK; Wannemuehler MJ; Bellaire BH; Narasimhan B
    Acta Biomater; 2024 Jul; 183():318-329. PubMed ID: 38844193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
    Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
    ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants.
    Wang S; Ding P; Shen L; Fan D; Cheng H; Huo J; Wei X; He H; Zhang G
    J Nanobiotechnology; 2024 Feb; 22(1):76. PubMed ID: 38414031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.
    Patel DR; Minns AM; Sim DG; Field CJ; Kerr AE; Heinly TA; Luley EH; Rossi RM; Bator CM; Moustafa IM; Norton EB; Hafenstein SL; Lindner SE; Sutton TC
    Microbiol Spectr; 2024 Mar; 12(3):e0499822. PubMed ID: 38334387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
    Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
    Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
    Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
    Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants.
    Wang W; Meng X; Cui H; Zhang C; Wang S; Feng N; Zhao Y; Wang T; Yan F; Xia X
    Int J Biol Macromol; 2024 Apr; 264(Pt 2):130820. PubMed ID: 38484812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancements in prophylactic and therapeutic nanovaccines.
    Bhardwaj P; Bhatia E; Sharma S; Ahamad N; Banerjee R
    Acta Biomater; 2020 May; 108():1-21. PubMed ID: 32268235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-adjuvanting polymeric nanovaccines enhance IFN production and cytotoxic T cell response.
    Zhao M; He C; Zheng X; Jiang M; Xie Z; Wei H; Zhang S; Lin Y; Zhang J; Sun X
    J Control Release; 2024 May; 369():556-572. PubMed ID: 38580136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
    Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
    ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endolysosomal-Escape Nanovaccines through Adjuvant-Induced Tumor Antigen Assembly for Enhanced Effector CD8
    Qiu L; Valente M; Dolen Y; Jäger E; Beest MT; Zheng L; Figdor CG; Verdoes M
    Small; 2018 Apr; 14(15):e1703539. PubMed ID: 29493121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Glance on Nanovaccine: A Potential Approach for Disease Prevention.
    Garg A; Agrawal R; Chopra H; Singh T; Chaudhary R; Tankara A
    Curr Pharm Biotechnol; 2024; 25(11):1406-1418. PubMed ID: 37861010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
    Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
    ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
    Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
    ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
    Yip T; Qi X; Yan H; Chang Y
    ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.